1
|
Tran A, Katz D. Variability of fibrinolytic activity in pregnant patients exposed to tissue plasminogen activator: an in vitro study utilizing rotational thromboelastometry. Int J Obstet Anesth 2024:103994. [PMID: 38632015 DOI: 10.1016/j.ijoa.2024.103994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 03/05/2024] [Accepted: 03/13/2024] [Indexed: 04/19/2024]
Abstract
BACKGROUND The investigation into the variability of fibrinolysis in obstetric patients is notably limited despite its relevance to postpartum hemorrhage. We investigate an in vitro model of fibrinolysis measured by rotational thromboelastrometry (ROTEM) in maternal blood samples with lysis stimulated by tissue plasminogen activator (tPA). METHODS Written informed consent was obtained from 19 patients at term pregnancy during admission to the labor and delivery unit. Patients who were taking medication affecting coagulation were excluded. Tissue plasminogen activator was added to whole blood samples to a final concentration of 100 or 220 ng/mL prior to ROTEM testing. RESULTS The addition of tPA produced high intra-individual fibrinolytic variability for clot firmness and lysis parameters. Patients responded differently to each tPA dose ranging from clot lysis within the range of 0 ng/mL tPA group to complete clot lysis. The coefficient of variation (CV) values for the 220 ng/mL tPA group were: EXTEM MCF 0.510, EXTEM LI30 1.601, FIBTEM MCF 0.349, FIBTEM LI30 2.097. CV values for the 100 ng/mL tPA group were: EXTEM MCF 0.144, EXTEM LI30 1.038, FIBTEM MCF 0.096, FIBTEM LI30 1.238. CONCLUSION We demonstrate a wide range of fibrinolytic response in the obstetric population to exogeneous tPA. We found subgroups of patients that were very responsive to tPA and insensitive to tPA. This study represents a preliminary exploration into classifying the obstetric fibrinolytic phenotypes. Further research will integrate relevant coagulation factors to establish a predictive model for testing susceptibility to lysis that can be applied at the point of care.
Collapse
Affiliation(s)
- A Tran
- City University of New York School of Medicine, New York, NY 10031, USA; Department of Anesthesiology, Pain and Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
| | - D Katz
- Department of Anesthesiology, Pain and Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| |
Collapse
|
2
|
Sylvia LG, Gold AK, Rakhilin M, Amado S, Modrow MF, Albury EA, George N, Peters AT, Selvaggi CA, Horick N, Rabideau DJ, Dohse H, Tovey RE, Turner JA, Schopfer DW, Pletcher MJ, Katz D, Deckersbach T, Nierenberg AA. Healthy hearts healthy minds: A randomized trial of online interventions to improve physical activity. J Psychosom Res 2023; 164:111110. [PMID: 36525851 DOI: 10.1016/j.jpsychores.2022.111110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 11/27/2022] [Accepted: 11/27/2022] [Indexed: 12/03/2022]
Abstract
INTRODUCTION Depressed individuals are more likely to die from cardiovascular disease (CVD) than those without depression. People with CVD have higher rates of depression than those without and have higher mortality rates if they have comorbid depression. While physical activity (PA) improves both, few people engage in enough. We compared self-guided internet-based cognitive behavior therapy (CBT) + Fitbit or mindfulness-based cognitive therapy (MBCT) + Fitbit, with Fitbit only to increase daily steps for participants with depression who have low PA. METHODS Adult participants (N = 340) were recruited from two online patient-powered research networks and randomized to one of three study interventions for 8 weeks with an additional 8 weeks of follow-up. Using linear mixed effects models, we evaluated the effect of the intervention on average daily steps (NCT03373110). RESULTS Average daily steps increased 2.8 steps per day in MBCT+Fitbit, 2.9 steps/day in CBT + Fitbit, but decreased 8.2 steps/day in Fitbit Only. These changes were not statistically different between the MBCT+Fitbit and CBT + Fitbit groups, but were different from Fitbit Only across the initial 8-week period. Group differences were not maintained across follow-up. Exploratory analyses identified comorbid anxiety disorders, self-reported PA, and employment status as moderators. DISCUSSION Changes in daily steps over both 8- and 16-week periods-regardless of intervention group-were minimal. The results emphasize the limits of using self-guided web-based psychotherapy with an activity tracker to increase PA in participants with a history of depression and low PA.
Collapse
Affiliation(s)
- Louisa G Sylvia
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
| | - Alexandra K Gold
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Marina Rakhilin
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | - Selen Amado
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | | | - Evan A Albury
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | - Nevita George
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | - Amy T Peters
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | | | - Nora Horick
- Biostatistics, Massachusetts General Hospital, Boston, MA, USA
| | - Dustin J Rabideau
- Harvard Medical School, Boston, MA, USA; Biostatistics, Massachusetts General Hospital, Boston, MA, USA
| | - Heidi Dohse
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | - Roberta E Tovey
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | - Jon A Turner
- Department of Information, Operations, and Management Sciences, Stern School of Business, New York University, New York, New York, USA
| | | | - Mark J Pletcher
- University of California San Francisco, San Francisco, CA, USA
| | - Doug Katz
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA
| | | | - Andrew A Nierenberg
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| |
Collapse
|
3
|
Gold AK, Albury EA, Rabideau DJ, Yu C, Katz D, Nierenberg AA, Sylvia LG. The relationship between suicidal thoughts and well-being among individuals with a history of depression and cardiovascular risk. Psychiatry Research Communications 2022; 2. [PMID: 35928432 PMCID: PMC9348629 DOI: 10.1016/j.psycom.2022.100059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Prior work demonstrates a relationship between suicidal behavior and mood disorders, as well as between suicidal behavior and cardiovascular risk. When cardiovascular risk and mood disorders co-occur, people with these comorbid conditions tend to experience worse outcomes than people with only one of these conditions. As such, given the relevance of suicidal thoughts and behaviors among those with cardiovascular risk and mood disorders, suicidal thoughts and behaviors may be of particular concern in the comorbid population. However, the factors that differentiate those with or without suicidal thoughts or behaviors are unknown. Self-reported well-being is one factor that is shown to hold a relationship with suicidal risk, and may be relevant in the comorbid population. Thus, we evaluated whether different levels of well-being relate to suicidal thoughts and behaviors among individuals (N = 340) with lifetime mood disorders and cardiovascular risk who participated in a 16-week online exercise study. Participants completed self-report assessments of lifetime (per the MINI International Neuropsychiatric Interview) and current (per the Patient Health Questionnaire-9) suicidal thoughts and behaviors, as well as a self-report assessment of well-being (per the WHO-5 Well-Being Index). We found that individuals with lifetime and current suicidal thinking had lower total WHO-5 scores over the study period. These data suggest that, among those with a history of depression and who have or are at-risk for cardiovascular disease, the risk of current or lifetime suicidal thoughts and behaviors may be increased for those who experience decreased well-being.
Collapse
|
4
|
Chelales E, Kwan M, Crouch B, Katz D, Sag A, Ramanujam N. Abstract No. 101 Ethanol gel enhances percutaneous intratumoral chemotherapy injection: in vitro and in vivo studies of drug retention, tumor destruction, and overall survival. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
5
|
Pan X, Hou Q, Xu J, MA Y, LI J, LI M, Su J, Shi X, Bracken W, Katz D. POS1332 TOWARD SAFER GLUCOCORTICOID THERAPY OF POLYMYALGIA RHEUMATICA. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundSPI-62 is a potent 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well as for treatment of Cushing’s syndrome and autonomous cortisol secretion. HSD-1, an intracellular enzyme, activates glucocorticoids in target tissues in which glucocorticoid medicines are associated with morbidity including liver, adipose, muscle, and skin. In Phase 1 clinical trials SPI-62 was generally well tolerated and associated with maximal liver and brain HSD-1 inhibition.ObjectivesTo demonstrate mitigation by SPI-62 of corticosterone (CORT) adverse effects in mouse.MethodsC57BL/6 male mice (age 7 weeks; n=14 per group) were administered CORT (100 g/mL in drinking water) and SPI-62 (by gavage in 0.5% HPMC; 0, 1, or 10 mg/kg/day or 10 mg/kg twice daily) for 35 days. A control group received no CORT or SPI-62. Body weight was assessed daily and food consumption twice weekly. Whole body muscle and fat amounts were measured at Days 0, 14, and 28 using an EchoMRI-130H body composition analyzer. Blood samples for fasting glucose and insulin were obtained at Days 1 (pre-dose), 15, 29, and 35. An open field test was conducted on Day 22. A grip strength test was performed on Day 28. After sacrifice on Day 36, gonadal, subcutaneous, retroperitoneal, and mesenteric fat, quadriceps, and tibialis anterior were dissected and weighed, and skin was formalin fixed and paraffin embedded.ResultsOne control mouse died due to accidental gavage injury. Two mice who received CORT + 0.5% HPMC died on Days 11 and 19. CORT resulted in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT-treated mice showed reduced body weight gain for 2 weeks then accelerated body weight gain. SPI-62 prevented body weight gain acceleration in a dose-dependent manner. CORT effects on dermal thickness and structure were less prominent in mice who also received SPI-62. No effect of CORT or SPI-62 was observed in the open field test. SPI-62 prevented CORT adverse effects of insulin resistance, increased adiposity, skeletal myoatrophy, and grip strength reduction (Table 1).Table 1.Observed percentage difference of treatment group mean, compared to control group mean, in CORT-treated miceSPI-62 treatmentnone1 mg/kg1x/day10 mg/kg1x/day10 mg/kg2x/dayHOMA-IR Day 15+422+428+104+8HOMA-IR Day 29+788+472+204+14HOMA-IR Day 35+3620+1270+324+92Body fat content Day 14*+110+72-13-7Body fat content Day 28*+166+102+63-12Gonadal fat weight*+151+74+39-1Subcutaneous fat weight*+471+121+83+7Retroperitoneal fat weight*+227+89+36+25Mesenteric fat weight*+240+133+124+71Body muscle content Day 14*-10-70+1Body muscle content Day 28*-15-8-6+3Quadriceps weight*-54-43-24-16Tibialis anterior weight*-35-29-5+5Grip strength-12+16+15+26*Normalized by body weight.ConclusionSPI-62 prevented several CORT adverse effects in mouse, demonstrating that blockade of local intracellular glucocorticoid activation by a HSD-1 inhibitor in target tissues can mitigate glucocorticoid toxicity. These results suggest that SPI-62 has potential to similarly mitigate adverse effects of glucocorticoid medications in human. A placebo-controlled Phase 2 clinical trial has been initiated to compare prednisolone effects with and without SPI-62. Up to 48 patients diagnosed with polymyalgia rheumatica, on stable prednisolone 10 mg daily for at least 2 weeks, and with stable disease inactivity based on acute phase biomarkers will continue prednisolone 10 mg daily for 4 weeks, during which they will receive SPI-62 or placebo for 2 weeks each. Acute phase and other immune function biomarkers, symptom measures, and biomarkers of prednisolone adverse effects will be assessed at baseline and after each 2-week period. After analysis of data from a first cohort of 12 patients the prednisolone dose might be adjusted, in blinded fashion, during the SPI-62 period to maintain equipotency on acute phase biomarker suppression.Disclosure of InterestsXingyu Pan: None declared, Qiongqiong Hou: None declared, Jiahui Xu: None declared, Yake Ma: None declared, Jiawen Li: None declared, Min Li: None declared, Jing Su: None declared, Xuerou Shi: None declared, William Bracken Consultant of: Sparrow Pharmaceuticals, David Katz Shareholder of: Sparrow Pharmaceuticals, Employee of: Sparrow Pharmaceuticals
Collapse
|
6
|
Sherwin M, Katz D. Using gastric ultrasound to assess gastric content in the pregnant patient. BJA Educ 2021; 21:404-407. [PMID: 34707884 DOI: 10.1016/j.bjae.2021.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2021] [Indexed: 11/30/2022] Open
Affiliation(s)
- M Sherwin
- Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA
| | - D Katz
- Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA
| |
Collapse
|
7
|
Maher P, Getrajdman C, Katz D. 82 Heparinase-Native Thromboelastometry Detects Hypercoagulability in COVID-19 Disease. Ann Emerg Med 2021. [PMCID: PMC8335425 DOI: 10.1016/j.annemergmed.2021.07.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
8
|
Heijkoop B, Bolton D, Katz D, Ryan A, Epstein J, Appu S. Cystic papillary adenoma of the seminal vesicle – A distinct histological entity. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01082-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Abstract
Background Primary Seminal Vesicle (SV) tumours are a rare entity, with most SV masses representing invasion of the SV by malignancy originating in an adjacent organ, most often the prostate. Previously reported primary SV epithelial tumours have included adenocarcinoma and cystadenoma, with limited prior reports of inracystic papillary structures.
Case presentation A 35-year-old male presented with azoospermia, intermittent macroscopic haematuria, and mild right iliac fossa and groin pain. A papillary appearing seminal vesicle mass was found on imaging and seminal vesicoscopy. The mass was robotically excised with diagnosis of benign cystic papillary adenoma made. Conclusion In this manuscript we describe a rare case of a benign cystic papillary adenoma of the seminal vesicle, a unique histological entity differentiated from cystadenoma of the Seminal Vesicle by its papillary component.
Collapse
Affiliation(s)
| | - D Bolton
- Austin Health, Melbourne, Australia
| | - D Katz
- Men's Health Melbourne, Melbourne, Australia
| | | | - J Epstein
- Johns Hopkins Hospital, Baltimore, USA
| | - S Appu
- Austin Health, Melbourne, Australia.,Department of Surgery, Monash University, Melbourne, Australia
| |
Collapse
|
10
|
Katz D, Farber MK. Can measuring blood loss at delivery reduce hemorrhage-related morbidity? Int J Obstet Anesth 2021; 46:102968. [PMID: 33774489 DOI: 10.1016/j.ijoa.2021.102968] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Revised: 02/03/2021] [Accepted: 02/14/2021] [Indexed: 10/22/2022]
Abstract
Quantitation of blood loss after vaginal and cesarean delivery has been advocated for the timely detection of postpartum hemorrhage and activation of protocols for resuscitation. Morbidity and mortality from postpartum hemorrhage is considered to be largely preventable and is attributed to delayed recognition with under-resuscitation or inappropriate resuscitation. Optimizing detection of postpartum hemorrhage through refining how blood loss is measured is therefore clinically relevant. In this review on quantitative blood loss for postpartum hemorrhage, recent advances in the methods used to quantitate blood loss will be reviewed, with a comparison of utility and precision for blood loss measurement after vaginal and cesarean delivery. Considerations for the implementation of a quantitative blood loss system on the labor and delivery unit, including its benefits and challenges, will be discussed. The existing evidence for impact of blood loss quantitation in obstetrics on hemorrhage-related morbidity will be delineated, along with knowledge gaps and future research priorities.
Collapse
Affiliation(s)
- D Katz
- Icaha School of Medicine at Mount Sinai, New York, NY, USA
| | - M K Farber
- Brigham and Women's Hospital, Boston, MA, USA.
| |
Collapse
|
11
|
Fleishman A, Khwaja K, Schold JD, Comer CD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, Kaplan B, Pavlakis M, Mandelbrot DA, Rodrigue JR. Pain expectancy, prevalence, severity, and patterns following donor nephrectomy: Findings from the KDOC Study. Am J Transplant 2020; 20:2522-2529. [PMID: 32185880 PMCID: PMC7483675 DOI: 10.1111/ajt.15861] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 02/14/2020] [Accepted: 03/03/2020] [Indexed: 01/25/2023]
Abstract
Postoperative pain is an outcome of importance to potential living kidney donors (LKDs). We prospectively characterized the prevalence, severity, and patterns of acute or chronic postoperative pain in 193 LKDs at six transplant programs. Three pain measurements were obtained from donors on postoperative Day (POD) 1, 3, 7, 14, 21, 28, 35, 41, 49, and 56. The median pain rating total was highest on POD1 and declined from each assessment to the next until reaching a median pain-free score of 0 on POD49. In generalized linear mixed-model analysis, the mean pain score decreased at each pain assessment compared to the POD3 assessment. Pre-donation history of mood disorder (adjusted ratio of means [95% confidence interval (CI)]: 1.40 [0.99, 1.98]), reporting "severe" on any POD1 pain descriptors (adjusted ratio of means [95% CI]: 1.47 [1.12, 1.93]) and open nephrectomy (adjusted ratio of means [95% CI]: 2.61 [1.03, 6.62]) were associated with higher pain scores across time. Of the 179 LKDs who completed the final pain assessment, 74 (41%) met criteria for chronic postsurgical pain (CPSP), that is, any donation-related pain on POD56. Study findings have potential implications for LKD education, surgical consent, postdonation care, and outcome measurements.
Collapse
Affiliation(s)
- A Fleishman
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - K Khwaja
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - JD Schold
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
| | - CD Comer
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA
| | - P Morrissey
- Transplant Center, Rhode Island Hospital, Providence, RI
| | - J Whiting
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - J Vella
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - LK Kayler
- Montefiore Einstein Center for Transplantation, Bronx, NY,Regional Center of Excellence for Transplantation & Kidney Care, Erie County Medical Center, University of Buffalo, Buffalo, NY
| | - D Katz
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - J Jones
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - B Kaplan
- Baylor Scott and White Health, Temple, TX
| | - M Pavlakis
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - DA Mandelbrot
- Department of Medicine, University of Wisconsin, Madison, WI
| | - JR Rodrigue
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | | |
Collapse
|
12
|
Anderson E, Pascoe C, Sathianathen N, Katz D, Murphy D, Lawrentshuk N. Sub-inguinal orchidectomy: A minimally invasive approach to open surgery. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34107-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Katz D, Wang R, O'Neil L, Gerber C, Lankford A, Rogers T, Gal J, Sandler R, Beilin Y. The association between the introduction of quantitative assessment of postpartum blood loss and institutional changes in clinical practice: an observational study. Int J Obstet Anesth 2020; 42:4-10. [DOI: 10.1016/j.ijoa.2019.05.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 04/03/2019] [Accepted: 05/09/2019] [Indexed: 12/17/2022]
|
14
|
Cheung F, Fathollahi A, Vertosick E, Jarvis TR, Katz D, Sandhu JS, Favorito LA. Editorial Comment: Dorsolateral fibromuscular tissue preservation during artificial urinary sphincter cuff placement is associated with low infection and erosion rates. Int Braz J Urol 2020; 46:124-125. [PMID: 31851469 PMCID: PMC6968916 DOI: 10.1590/s1677-5538.ibju.2020.01.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- F Cheung
- Memorial Sloan Kettering Cancer Center, USA
| | | | | | - TR Jarvis
- Prince of Wales Clinical School, Australia
| | - D Katz
- Men's Health Melbourne, USA
| | - JS Sandhu
- Memorial Sloan Kettering Cancer Center, USA
| | - Luciano A Favorito
- Universidade Estadual do Rio de Janeiro - Uerj, Brasil; Hospital Federal da Lagoa, Brasil
| |
Collapse
|
15
|
Maher P, Katz D, Afzal O, Richardson L. 47 Clotting Differences Using ROTEM Testing for Early Prediction of Adverse Pregnancy Outcomes. Ann Emerg Med 2019. [DOI: 10.1016/j.annemergmed.2019.08.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Bernie H, Nascimento B, Katz D, Tin A, Benfante N, Sjoberg D, Carlsson S, Vickers A, Mulhall J. 160 Predictors of Worsening Erectile Function in Men With Functional Erections Early After Radical Prostatectomy. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.01.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
Rodrigue JR, Schold JD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, Kaplan B, Fleishman A, Pavlakis M, Mandelbrot DA. Mood, body image, fear of kidney failure, life satisfaction, and decisional stability following living kidney donation: Findings from the KDOC study. Am J Transplant 2018; 18:1397-1407. [PMID: 29206349 PMCID: PMC5988866 DOI: 10.1111/ajt.14618] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 11/02/2017] [Accepted: 11/29/2017] [Indexed: 01/25/2023]
Abstract
Prior studies demonstrate that most living kidney donors (LKDs) report no adverse psychosocial outcomes; however, changes in psychosocial functioning at the individual donor level have not been routinely captured. We studied psychosocial outcomes predonation and at 1, 6, 12, and 24 months postdonation in 193 LKDs and 20 healthy controls (HCs). There was minimal to no mood disturbance, body image concerns, fear of kidney failure, or life dissatisfaction, indicating no incremental changes in these outcomes over time and no significant differences between LKDs and HCs. The incidence of any new-onset adverse outcomes postdonation was as follows: mood disturbance (16%), fear of kidney failure (21%), body image concerns (13%), and life dissatisfaction (10%). Multivariable analyses demonstrated that LKDs with more mood disturbance symptoms, higher anxiety about future kidney health, low body image, and low life satisfaction prior to surgery were at highest risk of these same outcomes postdonation. It is important to note that some LKDs showed improvement in psychosocial functioning from pre- to postdonation. Findings support the balanced presentation of psychosocial risks to potential donors as well as the development of a donor registry to capture psychosocial outcomes beyond the mandatory 2-year follow-up period in the United States.
Collapse
Affiliation(s)
- JR Rodrigue
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - JD Schold
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
| | - P Morrissey
- Transplant Center, Rhode Island Hospital, Providence, RI
| | - J Whiting
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - J Vella
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - LK Kayler
- Montefiore Einstein Center for Transplantation, Bronx, NY,Regional Center of Excellence for Transplantation & Kidney Care, Erie County Medical Center, University of Buffalo, Buffalo, NY
| | - D Katz
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - J Jones
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - B Kaplan
- Department of Medicine, University of Arizona, Tucson, AZ,School for the Science of Health Care Delivery, Arizona State University, Phoenix, AZ
| | - A Fleishman
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA
| | - M Pavlakis
- The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - DA Mandelbrot
- Department of Medicine, University of Wisconsin, Madison, WI
| | | |
Collapse
|
18
|
Westerman K, Reaver A, Blander G, Nogal B, Ward C, Benard T, Katz D, Blumberg J. An Algorithm-based Personalized Nutrition Platform Improves Metabolic Biomarkers. J Acad Nutr Diet 2017. [DOI: 10.1016/j.jand.2017.06.379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Guthrie KM, Rohan L, Rosen RK, Vargas SE, Shaw JG, Katz D, Kojic EM, Ham AS, Friend D, Buckheit KW, Buckheit RW. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design. Pharm Dev Technol 2017; 23:311-314. [PMID: 28592183 DOI: 10.1080/10837450.2017.1339085] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Topical prevention of HIV and other STIs is a global health priority. To provide options for users, developers have worked to design safe, effective and acceptable vaginal dissolving film formulations. We aimed to characterize user experiences of vaginal film size, texture and color, and their role in product-elicited sensory perceptions (i.e. perceptibility), acceptability and willingness to use. In the context of a user-centered product evaluation study, we elicited users' 'first impressions' of various vaginal film formulation designs via visual and tactile prototype inspection during a qualitative user evaluation interview. Twenty-four women evaluated prototypes. Participants considered size and texture to be important for easy insertion. Color was more important following dissolution than prior to insertion. When asked to combine and balance all properties to arrive at an ideal film, previously stated priorities for individual characteristics sometimes shifted, with the salience of some individual characteristics lessening when multiple characteristics were weighted in combination. While first impressions alone may not drive product uptake, users' willingness to initially try a product is likely impacted by such impressions. Developers should consider potential users' experiences and preferences in vaginal film design. This user-focused approach is useful for characterizing user sensory perceptions and experiences relevant to early design of prevention technologies.
Collapse
Affiliation(s)
- K M Guthrie
- a Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.,b Department of Psychiatry and Human Behavior , The Warren Alpert Medical School of Brown University , Providence , RI , USA.,c Department of Behavioral and Social Sciences , Brown University School of Public Health , Providence , RI , USA
| | - L Rohan
- d Magee-Womens Research Institute , Pittsburgh , PA , USA.,e University of Pittsburgh , Pittsburgh , PA , USA
| | - R K Rosen
- a Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.,c Department of Behavioral and Social Sciences , Brown University School of Public Health , Providence , RI , USA
| | - S E Vargas
- a Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.,b Department of Psychiatry and Human Behavior , The Warren Alpert Medical School of Brown University , Providence , RI , USA
| | - J G Shaw
- a Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA
| | - D Katz
- f Biomedical Engineering and Obstetrics/Gynecology, Duke University , Durham , NC , USA
| | - E M Kojic
- g Division of Immunology , The Miriam Hospital , Providence , RI , USA
| | - A S Ham
- h ImQuest BioSciences, Inc , Frederick , MD , USA
| | | | - K W Buckheit
- h ImQuest BioSciences, Inc , Frederick , MD , USA
| | - R W Buckheit
- h ImQuest BioSciences, Inc , Frederick , MD , USA
| |
Collapse
|
20
|
Hunter S, Katz D, Goldberg A, Lin HM, Pasricha R, Benesh G, Le Grand B, DeMaria S. Use of an anaesthesia workstation barrier device to decrease contamination in a simulated operating room. Br J Anaesth 2017; 118:870-875. [DOI: 10.1093/bja/aex097] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2017] [Indexed: 12/12/2022] Open
|
21
|
Grizzle RE, Ward KM, Peter CR, Cantwell M, Katz D, Sullivan J. Growth, morphometrics, and nutrient content of farmed eastern oysters, Crassostrea virginica (Gmelin), in New Hampshire, USA. Aquac Res 2017; 48:1525-1537. [PMID: 30123043 PMCID: PMC6093306 DOI: 10.1111/are.12988] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
When harvested, oysters represent a removal from the ecosystem of nutrients such as nitrogen (N) and carbon (C). A number of factors potentially affect nutrient content, but a quantitative understanding across the geographic range of the eastern oysters is lacking. The present study was designed to quantify the relationships among various metrics of farmed eastern oysters near its northern geographic range focusing on nutrient content. Hatchery-reared oysters were deployed in polyethylene bags at six sites, and were measured on multiple occasions from 2010-2012. A quadratic polynomial fit to the combined datasets for shell height indicated that on average a 'cocktail' size oyster (63 mm shell height) would be reached after 2 yr, and 'regular' size (76 mm) would require 3 yr. There were significant differences in growth rates and oyster nutrient content among the sites; means for %N in soft tissue ranged from 6.9 to 8.6, and 0.07 to 0.18 in shell. Percent N in soft tissue and shell were highest at two sites at the mouths of rivers with elevated dissolved inorganic N concentrations in the water. Grand means (all sites, seasons and years combined) of soft tissue N and C for regular size oysters were 7.3% and 38.5%, respectively; and for shell N and C were 0.13% and 12.0%, respectively. Our study extends the range of data on nutrient content of the eastern oyster to northern New England, and indicates that oyster size, seasonality, and nutrient concentration in ambient water potentially affect %N and %C content of oysters.
Collapse
Affiliation(s)
- R E Grizzle
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - K M Ward
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - C R Peter
- University of New Hampshire, Jackson Estuarine Laboratory, Durham, NH 03824 USA
| | - M Cantwell
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| | - D Katz
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| | - J Sullivan
- United States Environmental Protection Agency, Office of Research and Development, National Human and Environmental Effects Research Lab, Atlantic Ecology Division, Narragansett, RI 02882 USA
| |
Collapse
|
22
|
Alagheband S, Malet P, Katz D, Davis-Lorton M. Angioedema of the small intestine: A great imitator. Clin Res Hepatol Gastroenterol 2017; 41:121-122. [PMID: 27825635 DOI: 10.1016/j.clinre.2016.09.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 09/09/2016] [Accepted: 09/22/2016] [Indexed: 02/04/2023]
Affiliation(s)
- S Alagheband
- Winthrop University Hospital, Department of Internal Medicine, First Street, Mineola, NY 11501, United States.
| | - P Malet
- Winthrop University Hospital, Department of Gastroenterology, 222 Station Plz N Building, Suite 429, Mineola, NY 11501, United States.
| | - D Katz
- Winthrop University Hospital, Department of Radiology, First Street, Mineola, NY 11501, United States.
| | - M Davis-Lorton
- Winthrop University Hospital, Department of Allergy-Immunology, 120 Mineola Blvd, Suite 410, Mineola, NY 11501, United States.
| |
Collapse
|
23
|
Ravi V, Madison R, Schrock AB, Cote G, Millis S, Alvarez R, Choy E, Katz D, Chung J, Gay L, Miller VA, Ross JS, Ali SM, Schnitt S. Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Angiosarcoma of the breast (BAS) is a rare but lethal neoplasia, either arising de novo or secondary to radiation therapy, with incidence of the latter disease increasing. We queried a database of more than 70,000 advanced cancer patients assayed with comprehensive genomic profiling (CGP) in the course of clinical care to uncover the frequency, type and associated genomic alterations (GA) in BAS and to highlight possible routes to benefit from targeted therapy.
Methods: CGP was performed for 34 BAS cases using a hybrid-capture, adaptor ligation based next generation sequencing assay of up to 315 genes to a mean coverage depth of >500X. The results were analyzed for base substitutions, short insertions and deletions, selected rearrangements, and copy number changes. RNA sequencing for 265 genes was also performed for 24 cases. Limited clinical histories from submitted pathology reports were reviewed under IRB permission.
Results: Clinical specimens from 34 BAS patients, all females, were assayed. The cases harbored 87 total GA for a mean of 2.59 per case, 25% of which were copy number amplifications. The most commonly altered genes were MYC (41%, 14/34), PIK3CA (26%, 9/34), and KDR (26%, 9/34). All MYC alterations were amplifications with a mean copy number of 39, and alterations in other MYC family members (MYCN and MYCL1) were not observed. KDR was recurrently altered as T771R (7/9) and T771K (1/9) and amplified in one case (1/9).
MYC and KDR alterations were mutually exclusive (p<0.0001). 6/14 MYC amplified cases had prior histories of breast carcinoma, with 3/6 noted as being treated with radiation therapy. For the remainder of MYC amplified cases (8/14), no relevant clinical history was available.
Two cases harboring gene fusions were identified including CIC-MEGF8 and NTRK1-PEAR1. Two rearrangements of potential functional significance including CIC-DEDD2 and HT-ALK (exon1 HT - exon5-29 ALK including kinase domain) were also observed. The case harboring HT-ALK also had MYC amplification and known prior radiation therapy. Two other MYC amplified cases also harbored targetable kinase alterations, including FLT4 amplification (described as targetable in Ravi et al JNCCN 2016) and FGFR3 S249C, a known activating mutation.
Conclusions: MYC amplification defines over 40% (14/34) of advanced BAS cases. Of MYC amplified cases, 28% (4/14) harbored targetable alterations of tyrosine kinases including a potential novel ALK fusion. FLT4 amplification only co-occurred with MYC amplification, but this result was not statistically significant in this small series. KDR and MYC alteration were mutually exclusive, and 45% of non-MYC altered cases (9/20) harbored KDR alterations, which were predominantly mutations of T771. Further clinico-pathologic correlation, particularly history of radiation therapy, will be explored in this series, as well defining BAS that harbor neither MYC nor KDR alterations.
Citation Format: Ravi V, Madison R, Schrock AB, Cote G, Millis S, Alvarez R, Choy E, Katz D, Chung J, Gay L, Miller VA, Ross JS, Ali SM, Schnitt S. Comprehensive genomic profiling of 34 cases of breast angiosarcoma [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-12-01.
Collapse
Affiliation(s)
- V Ravi
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - R Madison
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - AB Schrock
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - G Cote
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - S Millis
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - R Alvarez
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - E Choy
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - D Katz
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - J Chung
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - L Gay
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - VA Miller
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - JS Ross
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - SM Ali
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| | - S Schnitt
- Foundation Medicine, Inc; Massachusetts General Hospital; Dana Farber Cancer Institute; Southeastern Regional Medical Center; Beth Israel Deaconness Medical Center; Hadassah-Hebrew University Medical Center
| |
Collapse
|
24
|
Techasith T, Hoang D, Reposar A, Kuo W, Hovsepian D, Katz D, Hofmann L. Ovarian vein embolization for treatment of lower extremity edema in patients with ovarian vein enlargement/reflux: A single-institution feasibility study. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.1184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
25
|
Baadh A, Katz D, Islam S, Baadh P. Interventional radiology and the Sunshine Act: Two -year analysis of the open payments database and comparison with related specialties. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017; 56:88-92. [PMID: 27838944 DOI: 10.1080/0284186x.2016.1234068] [Citation(s) in RCA: 122] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. PATIENTS AND METHODS A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed. RESULTS Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively. CONCLUSION The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Collapse
Affiliation(s)
- A. Kollár
- Sarcoma Unit, Department of Medical Oncology, University Hospital of Bern, Bern, Switzerland
| | - R. L. Jones
- Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - S. Stacchiotti
- Sarcoma Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - H. Gelderblom
- Department of Medical Oncology, Leiden University Medical Center, RC Leiden, The Netherlands
| | - M. Guida
- Oncology Department, National Cancer Institute "Giovanni Paolo II", Bari, Italy
| | - G. Grignani
- Division of Medical Oncology, Candiolo Cancer Institue–FPO, IRCCS, Candiolo, Italy
| | - N. Steeghs
- Department of Medical Oncology, Pharmacology the Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - A. Safwat
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - D. Katz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Kiryat Hadassah, Jerusalem, Israel
| | - F. Duffaud
- La Timone University Hospital & Aix-Marseille University (AMU), Marseille, France
| | - S. Sleijfer
- Department of Medical Oncology, Erasmus MC–Cancer Institute, Erasmus University Medical Center, CE Rotterdam, The Netherlands
| | - W. T. van der Graaf
- Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
- Department of Medical Oncology, Radboud University Medical Center, GA Nijmegen, The Netherlands
| | - N. Touati
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - S. Litière
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - S. Marreaud
- European Organization for Research and Treatment of Cancer (EORTC), Bruxelles, Belgium
| | - A. Gronchi
- Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - B. Kasper
- Sarcoma Unit, Interdisciplinary Tumor Center, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
27
|
Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? Clin Pharmacol Ther 2016; 101:230-238. [DOI: 10.1002/cpt.568] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Accepted: 11/09/2016] [Indexed: 02/07/2023]
Affiliation(s)
- D Katz
- The Zabludowicz Center for Autoimmune Diseases; Chaim Sheba Medical Center; Tel-Hashomer Israel
- Faculty of Medicine; The Hebrew University of Jerusalem; Israel
| | - I Katz
- The Zabludowicz Center for Autoimmune Diseases; Chaim Sheba Medical Center; Tel-Hashomer Israel
- Faculty of Medicine; The Hebrew University of Jerusalem; Israel
| | - BS Porat-Katz
- The Robert H. Smith Faculty of Agriculture, Food and Environment School of Nutritional Sciences; The Hebrew University of Jerusalem; Rehovot Israel
| | - Y Shoenfeld
- The Zabludowicz Center for Autoimmune Diseases; Chaim Sheba Medical Center; Tel-Hashomer Israel
- Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine; Tel-Aviv University; Israel
| |
Collapse
|
28
|
Alagheband S, Katz D, Davis-Lorton M. P092 Angiotensin-converting enzyme-inhibitor-induced small bowel angioedema. Ann Allergy Asthma Immunol 2016. [DOI: 10.1016/j.anai.2016.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Kollar A, Jones R, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van sder Graaf W, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw388.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Katz D, Azraq Y, Eleyan F, Gill S, Peretz T, Merimsky O. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis. BMC Cancer 2016; 16:616. [PMID: 27501793 PMCID: PMC4977830 DOI: 10.1186/s12885-016-2618-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 07/26/2016] [Indexed: 11/16/2022] Open
Abstract
Background To explore the activity of pazopanib (P) + sirolimus (S) in patients who progressed after previous clinical benefit on pazopanib. Methods Eight patients with progressing metastatic high grade soft tissue sarcoma (STS) whose disease advanced on P following a response duration of at least 4 months were offered re-challenge of P supplemented by off-label S and a single patient with progressing metastatic chondrosarcoma was offered the combination as compassionate treatment. Patients were treated in two centers: Hadassah Medical Center and Tel Aviv Medical Center. Patients received oral P 200–600 mg once a day supplemented by S 3–4 mg taken separately, 12 h after the P dose. Results Patients received treatment from December 2012 to February 2016. Four progressed on the combination and their treatment was terminated. Two patients were undergoing treatment when data was summarized. Best Response Evaluation Criteria in Solid Tumour (RECIST) responses were: one partial response (PR), four stable disease (SD), and four progressive disease (PD), corresponding to five PR and four PD on the Choi criteria. Median progression free survival was 5.5 months (range 4–17). Conclusions Our series showed that the combination of P + S has activity in STS patients selected by previous response to P and in a patient with chondrosarcoma, suggesting this can serve as a mechanism to reverse resistance to P and extend the chemotherapy-free window.
Collapse
Affiliation(s)
- D Katz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
| | - Y Azraq
- Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - F Eleyan
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - S Gill
- Boston University School of Medicine, Boston, USA
| | - T Peretz
- Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - O Merimsky
- The Unit of Bone and Soft Tissue Oncology, Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.,Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| |
Collapse
|
32
|
Love C, Katz D. 143 Medium-term Outcomes of the MINT Technique for IPP Surgery in 180 Consecutive Patients. J Sex Med 2016. [DOI: 10.1016/j.jsxm.2016.02.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Rodrigue JR, Schold JD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, Kaplan B, Fleishman A, Pavlakis M, Mandelbrot DA. Direct and Indirect Costs Following Living Kidney Donation: Findings From the KDOC Study. Am J Transplant 2016; 16:869-76. [PMID: 26845630 DOI: 10.1111/ajt.13591] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 09/11/2015] [Accepted: 09/23/2015] [Indexed: 01/25/2023]
Abstract
Some living kidney donors (LKDs) incur costs associated with donation, although these costs are not well characterized in the United States. We collected cost data in the 12 mo following donation from 182 LKDs participating in the multicenter prospective Kidney Donor Outcomes Cohort (KDOC) Study. Most LKDs (n = 167, 92%) had one direct cost or more following donation, including ground transportation (86%), health care (41%), meals (53%), medications (36%), lodging (23%), and air transportation (12%). LKDs missed 33 072 total work hours, 40% of which were unpaid and led to $302 175 in lost wages (mean $1660). Caregivers lost $68 655 in wages (mean $377). Although some donors received financial assistance, 89% had a net financial loss in the 12-mo period, with one-third (33%) reporting a loss exceeding $2500. Financial burden was higher for those with greater travel distance to the transplant center (Spearman's ρ = 0.26, p < 0.001), lower household income (Spearman's ρ = -0.25, p < 0.001), and more unpaid work hours missed (Spearman's ρ = 0.52, p < 0.001). Achieving financial neutrality for LKDs must be an immediate priority for the transplant community, governmental agencies, insurance companies, nonprofit organizations, and society at large.
Collapse
Affiliation(s)
- J R Rodrigue
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.,Harvard Medical School, Boston, MA
| | - J D Schold
- Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
| | - P Morrissey
- Transplant Center, Rhode Island Hospital, Providence, RI
| | - J Whiting
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - J Vella
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - L K Kayler
- Montefiore Einstein Center for Transplantation, Bronx, NY.,Regional Center of Excellence for Transplantation and Kidney Care, Erie County Medical Center, University of Buffalo, Buffalo, NY
| | - D Katz
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - J Jones
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - B Kaplan
- Department of Medicine, University of Arizona, Tucson, AZ.,School for the Science of Health Care Delivery, Arizona State University, Phoenix, AZ
| | - A Fleishman
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA
| | - M Pavlakis
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.,Harvard Medical School, Boston, MA
| | - D A Mandelbrot
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.,Department of Medicine, University of Wisconsin, Madison, WI
| | | |
Collapse
|
34
|
Affiliation(s)
- H Meldrum
- a Australasian Society for Lifestyle Medicine , Northcote , Melbourne, Australia
| | - D Katz
- b American College of Lifestyle Medicine , Woodburn , OR , USA
| | - G Egger
- a Australasian Society for Lifestyle Medicine , Northcote , Melbourne, Australia
| |
Collapse
|
35
|
|
36
|
Mazzola C, Berookhim B, Katz D, Deveci S, Mulhall J. Arrêter un traitement par citrate de clomiphène pour commencer un traitement par testostérone transdermique : impact sur la symptomatologie de l’hypogonadisme. Prog Urol 2015; 25:815-6. [DOI: 10.1016/j.purol.2015.08.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Katz D, Patel K, Nichols E, Rosenblatt P, Tkaczuk K, Baron K, Heiss B, Marshall J, Tait N, Gottlieb S, Feigenberg S. The Use of Radiation Therapy Does Not Appear to Have an Impact on the Incidence of Heart Failure in Patients Receiving Targeted HER2 Based Systemic Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Rodrigue JR, Schold JD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, Kaplan B, Fleishman A, Pavlakis M, Mandelbrot DA. Predonation Direct and Indirect Costs Incurred by Adults Who Donated a Kidney: Findings From the KDOC Study. Am J Transplant 2015; 15:2387-93. [PMID: 25943721 PMCID: PMC5097875 DOI: 10.1111/ajt.13286] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Revised: 02/22/2015] [Accepted: 02/26/2015] [Indexed: 01/25/2023]
Abstract
Limited information exists on the predonation costs incurred by eventual living kidney donors (LKDs). Expenses related to completion of the donation evaluation were collected from 194 LKDs participating in the multi-center, prospective Kidney Donor Outcomes Cohort (KDOC) Study. Most LKDs (n = 187, 96%) reported one or more direct costs, including ground transportation (80%), healthcare (24%), lodging (17%) and air transportation (14%), totaling $101 484 (USD; mean = $523 ± 942). Excluding paid vacation or sick leave, donor and companion lost wages totaled $35 918 (mean = $187 ± 556) and $14 378 (mean = $76 ± 311), respectively. One-third of LKDs used paid vacation or sick leave to avoid incurring lost wages. Few LKDs reported receiving financial support from the transplant candidate (6%), transplant candidate's family (3%), a nonprofit organization (3%), the National Living Donor Assistance Center (7%), or transplant center (3%). Higher total costs were significantly associated with longer distance traveled to the transplant center (p < 0.001); however, total costs were not associated with age, sex, race/ethnicity, household income, marital status, insurance status, or transplant center. Moderate predonation direct and indirect costs are common for adults who complete the donation evaluation. Potential LKDs should be advised of these possible costs, and the transplant community should examine additional strategies to reimburse donors for them.
Collapse
Affiliation(s)
- J. R. Rodrigue
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA,Corresponding author: James R. Rodrigue,
| | - J. D. Schold
- Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
| | - P. Morrissey
- Transplant Center, Rhode Island Hospital, Providence, RI
| | - J. Whiting
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - J. Vella
- Maine Transplant Center, Maine Medical Center, Portland, ME
| | - L. K. Kayler
- Montefiore Einstein Center for Transplantation, Bronx, NY
| | - D. Katz
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - J. Jones
- Organ Transplantation Program, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - B. Kaplan
- Division of Internal Medicine, University of Kansas Medical Center, Kansas City, KS,Department of Medicine, University of Arizona, Tucson, AZ
| | - A. Fleishman
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - M. Pavlakis
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Harvard Medical School, Boston, MA
| | - D. A. Mandelbrot
- Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA,Department of Medicine, University of Wisconsin, Madison, WI
| | | |
Collapse
|
39
|
Hoger S, Lykens K, Beavers SF, Katz D, Miller TL. Longevity loss among cured tuberculosis patients and the potential value of prevention. Int J Tuberc Lung Dis 2015; 18:1347-52. [PMID: 25299869 DOI: 10.5588/ijtld.14.0242] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Evidence of substantial, quantifiable and preventable burdens of mortality hazard even after anti-tuberculosis treatment and cure would be a compelling, concrete, and useful measure of the value of prevention. METHODS We compared years of potential life lost between a cohort of 3 933 cured tuberculosis (TB) patients and 9 166 persons with latent tuberculous infection. We constructed a regression model to predict the expected years of potential life lost in each cohort and for demographic subgroups. RESULTS Among decedents, a history of fully treated TB is associated with a predicted average 3.6 more years of potential life loss than a comparable population without active TB. Greater longevity losses were predicted among those identified as White and Hispanic than among Black and Asian counterparts. CONCLUSION We found significant differences in predicted longevity of treated TB survivors relative to a similar group without active TB. These excess losses are substantial: a total of 14 158 life-years or the equivalent of more than 188 75-year lifespans. These findings illustrate an important opportunity cost associated with each preventable TB case - an average of 3.6 potential years of life. We conclude that substantial preventable mortality burdens remain despite adequate anti-tuberculosis treatment, a compelling rationale for more widespread and systematic use of prevention.
Collapse
Affiliation(s)
- S Hoger
- Tarleton State University, Fort Worth, Texas, USA
| | - K Lykens
- University of North Texas Health Science Center, Fort Worth, Texas, USA
| | - S F Beavers
- Centers for Disease Prevention and Control, Atlanta, Georgia, USA
| | - D Katz
- Centers for Disease Prevention and Control, Atlanta, Georgia, USA
| | - T L Miller
- University of North Texas Health Science Center, Fort Worth, Texas, USA
| |
Collapse
|
40
|
Goldberg A, Silverman E, Samuelson S, Katz D, Lin H, Levine A, DeMaria S. Learning through simulated independent practice leads to better future performance in a simulated crisis than learning through simulated supervised practice †. Br J Anaesth 2015; 114:794-800. [DOI: 10.1093/bja/aeu457] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/10/2014] [Indexed: 11/12/2022] Open
|
41
|
Egger G, Katz D, Sagner M, Dixon J, Stevens J. The art and science of chronic disease management come together in a lifestyle-focused approach to primary care. Int J Clin Pract 2014; 68:1406-9. [PMID: 25418526 DOI: 10.1111/ijcp.12500] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Accepted: 06/18/2014] [Indexed: 11/29/2022] Open
Abstract
Changes in patterns of living result in changes in the nature and causes of disease. The industrial revolution of the late 18th century, and the technological revolution of the late 20th century are cases in point. The former was associated with a decline in infectious diseases; the latter with an increase in lifestyle and environmentally induced chronic diseases . Health practices are typically modified to deal with such changes, hence the recent rise in interest in lifestyle-oriented forms of clinical practice.
Collapse
Affiliation(s)
- G Egger
- Australian Lifestyle Medicine Association (ALMA), Sydney, Australia; Health and Human Sciences, Southern Cross University, Lismore, NSW, Australia
| | | | | | | | | |
Collapse
|
42
|
Sagner M, Katz D, Egger G, Lianov L, Schulz KH, Braman M, Behbod B, Phillips E, Dysinger W, Ornish D. Lifestyle medicine potential for reversing a world of chronic disease epidemics: from cell to community. Int J Clin Pract 2014; 68:1289-92. [PMID: 25348380 DOI: 10.1111/ijcp.12509] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Accepted: 06/25/2014] [Indexed: 01/05/2023] Open
Affiliation(s)
- M Sagner
- European Society of Lifestyle Medicine, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Krishnan R, Katz D, Nelson CJ, Mulhall JP. Erectile function recovery in patients after non-nerve sparing radical prostatectomy. Andrology 2014; 2:951-4. [PMID: 25270277 DOI: 10.1111/andr.282] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2014] [Accepted: 09/03/2014] [Indexed: 01/07/2023]
Abstract
Few studies have looked at erectile function recovery (EFR) rates in men undergoing non-nerve sparing resection during radical prostatectomy (RP). Existing studies show great variation in EFR rates owing to multiple factors that minimize their utility in counselling RP patients. We investigated the EFR rate and its predictors in unilateral cavernous nerve resection and bilateral cavernous nerve resection patients 24 months after RP. We conducted a population-based, prospective cohort study of 966 patients who underwent RP at a tertiary cancer centre from 2008 to 2012. Cavernous nerve condition was evaluated on a 4-point nerve sparing score and assigned to one of three groups: bilateral sparing, unilateral resection (UNR) and bilateral nerve resection (BNR). EF was assessed pre-RP and 24-30 months post-op using a validated 5-point patient-reported scale (1 = fully rigid; 5 = no tumescence). EFR was defined as a post-op EF grade of 1-2. Statistical analysis included descriptive statistics, anova, chi-square, Fisher's exact test and logistic regression. Mean baseline EF was 1.84 ± 1.3 and 2.74 ± 1.5 for UNR and BNR patients respectively. Thirty-three percent of UNR patients and 13% of BNR patients exhibited EFR. Age, baseline EF were predictors of EFR. Multivariable analysis showed baseline EF was a significant predictor of EFR at 24 months for UNR. For BNR patients, pre-RP EF was the only factor predictive of EFR. Patients undergoing nerve resection still have a significant chance of achieving true EFR, with UNR surgery patients showing more potential for improvement than patients undergoing BNR surgery. Age and baseline EFR characterize recovery prospects in these two groups. Physicians should thus measure and account for baseline EF in addition to age and the degree of nerve resection when advising patients about expectations for successful EF following RP.
Collapse
Affiliation(s)
- R Krishnan
- Division of Urology, Sexual and Reproductive Medicine Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | |
Collapse
|
44
|
Maqdes A, Abarca J, Moraiti C, Boughebri O, Dib C, Leclère FM, Kany J, Elkolti K, Garret J, Katz D, Valenti P. Does preoperative subscapularis fatty muscle infiltration really matter in anterosuperior rotator cuff tears repair outcomes? A prospective multicentric study. Orthop Traumatol Surg Res 2014; 100:485-8. [PMID: 24947497 DOI: 10.1016/j.otsr.2014.02.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2013] [Revised: 11/18/2013] [Accepted: 02/20/2014] [Indexed: 02/02/2023]
Abstract
INTRODUCTION Anterosuperior (AS) rotator cuff tear describes a combined tear of the subscapularis and the supraspinatus tendons. We hypothesized that results after AS tendon repairs might be influenced by the size of the subscapularis rupture and the preoperative subscapularis muscle fatty infiltration. METHODS A prospective multicentric study of 53 AS rotator cuff tears from five centers was performed (January 2008-January 2009). Subscapularis tendon retraction and fatty infiltration were assessed preoperatively. An ultrasonographic healing control was performed 1 year after surgery. RESULTS Patients were on average 60 years (range, 43-75 years) and were operated on average 16 months (range, 2-72 months) after the beginning of their symptoms. The incidence of AS tears was found to be 18%. Average follow-up was 15 months (range, 12-24). The Constant-Murley (CM) score for the patients with AS ruptures improved significantly from 49 points (range, 35-51 points) preoperatively to 73 points postoperatively (range, 50-95 points)(P=0.0205). CM score gains were 26 for Lafosse group 1 ruptures and 29 for Lafosse group 2 & 3 with pre- and postoperative P values at P<0.0000001 and P<0.000001, respectively. The last follow-up CM score according to the subscapularis fatty infiltration was 70 (range, 48-95) for groups 0-1, 70 (range, 56-87) for group 2, and 56 (range, 53-88) for groups 3-4 with pre- and postoperative P values at P<0.001, P<0.001, and P<0.004, respectively. The global retear rate was 6%. DISCUSSION Our study showed that the CM score after repairs of AS rotator cuff tears was lower in advanced subscapularis fatty infiltration. However, gains in CM scores were similar whatever the initial subscapularis fatty infiltration. The rate of tendon healing was correlated with subscapularis fatty infiltration. Subscapularis tendon rupture size was not significantly correlated with outcomes. LEVEL OF EVIDENCE Level III.
Collapse
Affiliation(s)
- A Maqdes
- Clinique Jouvenet, 6, square Jouvenet, 75016 Paris, France.
| | - J Abarca
- Clinique Jouvenet, 6, square Jouvenet, 75016 Paris, France
| | - C Moraiti
- Clinique Jouvenet, 6, square Jouvenet, 75016 Paris, France
| | - O Boughebri
- Hôpital Privé Armand-Brillard, 3-5, avenue Watteau, 94130 Nogent-sur-Marne, France
| | - C Dib
- Clinique la Montagne, 10, rue de la Montage, 92400 Courbevoie, France
| | - F M Leclère
- Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J Kany
- Clinique de L'Union, boulevard Ratalens, 31240 Saint-Jean, France
| | - K Elkolti
- Institut Chirurgical de la Main et du Membre Supérieur, 17, avenue Condorcet, 69100 Villeurbanne, France
| | - J Garret
- Clinique du Parc, 155 ter, boulevard de Stalingrad, 69006 Lyon, France
| | - D Katz
- Clinique du Ter, chemin de Kerbernès, 56270 Ploemeur, France
| | - P Valenti
- Clinique Jouvenet, 6, square Jouvenet, 75016 Paris, France
| |
Collapse
|
45
|
Halpern N, Sonnenblick A, Kaduori L, Uziely B, Goldberg Y, Katz D, Allweis T, Divinsky L, Merlet I, Maly B, Sagi M, Hamburger T, Carmon E, Peretz T. Abstract P4-05-08: Oncotype Dx assay in BRCA positive ER positive breast cancer patients. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-05-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Oncotype DX is a 21-gene RT-PCR assay which quantifies the likelihood of breast cancer recurrence and the potential benefit of chemotherapy in patients with early stage, ER positive, Tamoxifen treated breast cancer. Breast cancer in BRCA carriers is considered more aggressive. The aim of our study was to evaluate whether Oncotype Dx recurrence score distribution is different in breast cancer patients with inherited BRCA mutation.
Methods:
The Oncotype DX assay has been used at Hadassah Medical Center since 2004 on specimens from over 450 patients. We analyzed and compared clinicopathological characteristics and Oncotype Dx recurrence scores of BRCA carriers versus non- BRCA or unknown status of BRCA patients.
Results:
Ten patients had validated inherited BRCA mutation, five of them are BRCA1 carriers and five BRCA2 carriers. There were no significant differences in the clinicopathological characteristics between the two groups. Oncotype Dx recurrence score distribution between low, intermediate and high risk groups was not significantly different. The mean recurrence score was 18.48 for the non- BRCA or unknown status of BRCA patients and 22.8 for the BRCA carriers patients. This difference was not statistically significant.
Conclusion:
Estrogen receptor positive breast cancer tumors from BRCA carriers does not display a significantly different Oncotype Dx recurrence score result distribution.
These preliminary data suggest Oncotype Dx assay might be used to help tailor treatment in this subset of patients, although further follow up is needed.
All patients evaluated for oncotype_DX All evaluated (except BRCA+) n = 456BRCA positiveP valueAgeMean57.4557.60.7 Median5857 Range56 (25-81)34 (42-76) T stageT167.7%70%0.9 T230.7%30% T31.6%0% Tumor sizeMean1.71.360.2 Median1.51.26 Range7.8 (0.2-8)1.3 (0.7-2) GradeGrade 1-278.8%60%0.15 Grade 321.2%40% RSLow50%40%0.57 Intermediate39.8%40% High10.2%20% RSMean18.4822.80.16 Median17.522.5 Range64 (0-64)27 (12-39)
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-05-08.
Collapse
Affiliation(s)
- N Halpern
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - A Sonnenblick
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - L Kaduori
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - B Uziely
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - Y Goldberg
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - D Katz
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - T Allweis
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - L Divinsky
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - I Merlet
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - B Maly
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - M Sagi
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - T Hamburger
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - E Carmon
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| | - T Peretz
- Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel
| |
Collapse
|
46
|
Guitelman M, Garcia Basavilbaso N, Vitale M, Chervin A, Katz D, Miragaya K, Herrera J, Cornalo D, Servidio M, Boero L, Manavela M, Danilowicz K, Alfieri A, Stalldecker G, Glerean M, Fainstein Day P, Ballarino C, Mallea Gil MS, Rogozinski A. Primary empty sella (PES): a review of 175 cases. Pituitary 2013; 16:270-4. [PMID: 22875743 DOI: 10.1007/s11102-012-0416-6] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The term primary empty sella (PES) makes reference to the herniation of the subarachnoid space within the sella turcica in patients with no history of pituitary tumor, surgery or radiotherapy. To retrospectively assess clinical features, radiological findings and the biochemical endocrine function from the records of 175 patients with a diagnosis of PES. One hundred seventy-five patients (150 females) were studied. The mean age at diagnosis was 48.2 ± 14 year. Most diagnoses were made by magnetic resonance imaging (n = 172). In most patients, the pituitary function was assessed by basal pituitary hormones measurements. Pituitary scans were ordered for different reasons: headache (33.1 %), endocrine disorders (30.6 %), neurological symptoms (12.5 %), visual disturbances (8.75 %), abnormalities on sella turcica radiograph (8.75 %) and others (6.25 %). Multiple pregnancies were observed in 58.3 % of women; headaches, obesity, and hypertension were found in 59.4, 49.5, and 27.3 % of the studied population, respectively. Mild hyperprolactinemia (<50 ng/ml) was present in 11.6 % of women and 17.3 % of men. Twenty-eight percent of our patients had some degree of hypopituitarism. In the male population, hypopituitarism represented 64 % of cases, whereas it accounted for 22 % of all females. PES seems to be more commonly found in middle-aged women, with a history of multiple pregnancies. In most patients, PES was discovered as an incidental finding on imaging studies, while in almost a quarter of patients PES was found during the diagnostic evaluation of anterior pituitary deficiency, which was more common in men.
Collapse
Affiliation(s)
- M Guitelman
- Departamento de Neuroendocrinología, Sociedad Argentina de Endocrinología y Metabolismo, Díaz Vélez 3889, C1200AAF Ciudad Autónoma de Bs As, Argentina.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Collins J, Kalisz K, Benefield B, Sarnari R, Katz D, Bi X, Cordts M, Guetter C, Jolly MP, Freed B, Flukiger J, Kansal P, Lee D, Shah S, Markl M, Carr J. 1046Cardiac MR left ventricular myocardial strain derived
from deformation fields using balanced steady state free precession cine imaging
in patients with scleroderma. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet070cb] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Kalisz K, Semaan E, Katz D, Bi X, Cordts M, Guetter C, Jolly MP, Freed B, Flukiger J, Lee D, Kansal P, Shah S, Markl M, Carr J, Collins J. 1047Cardiac MR left ventricular myocardial strain derived
from deformation fields using balanced steady state free precession cine imaging
in patients with cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2013. [DOI: 10.1093/ehjci/jet070be] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Katz D, Kany J, Valenti P, Sauzières P, Gleyze P, El Kholti K. New design of a cementless glenoid component in unconstrained shoulder arthroplasty: a prospective medium-term analysis of 143 cases. Eur J Orthop Surg Traumatol 2013; 23:27-34. [PMID: 23293576 PMCID: PMC3535408 DOI: 10.1007/s00590-012-1109-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2012] [Accepted: 10/09/2012] [Indexed: 11/18/2022]
Abstract
The uncemented glenoid implants in total anatomical shoulder arthroplasty are likely to be accused of problems like dissociations, secondary rotator cuff tear, and wear of polyethylene (PE). This work is a clinical and radiological prospective review of 143 cases of anatomical total shoulder arthroplasty using a new metal back uncemented glenoid implant (MB) in order to see if this new implant induces those complications. A total of 143 cases were operated between 2003 and 2011. In a first part, the whole series of 143 cases was radiologically studied in order to quantify the lateralisation induced by the MB implant. In a second study, 37 cases had a mean follow-up of 38 months (24-75, mean 32) and served for the clinical and radiological final study. Pre- and postoperative clinical evaluation was done using the Constant-Murley score and the simple shoulder test from Matsen. The final X-rays served to detect an eventual secondary narrowing of the joint space and to analyse the frequency of radio lucent lines (RLL) and loosenings. Despite a small radiological lateralisation in comparison with the normal contralateral side (0.36 cm, p = 0.02), the clinical results after 2 years were similar to the published cemented glenoid implants series but without any RLL, glenoid loosening or joint narrowing. Some dissociations occured in the beginning and definitely eliminated by a design modification of the PE tray. The discussion tried to show that, despite a still short follow-up, this series is encouraging to continue to use this new MB implant. Different applications of the concept of universality and conversion are discussed, this tray been also the support of a glenosphere in reverse arthroplasty.
Collapse
Affiliation(s)
- D Katz
- Clinique du Ter, 56270 Ploemeur, France.
| | | | | | | | | | | |
Collapse
|
50
|
Mazzola C, Katz D, Logmanieh N, Mulhall J. Prédire la réponse au citrate de clomifène chez les patients ayant un hypogonadisme. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|